These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 34269764)

  • 1. Acquired Epiblepharon Alleviated With Teprotumumab Treatment in Active Thyroid Eye Disease Patient.
    Chen KW; Phelps PO
    Ophthalmic Plast Reconstr Surg; 2021 Nov-Dec 01; 37(6):e195-e196. PubMed ID: 34269764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials.
    Kahaly GJ; Douglas RS; Holt RJ; Sile S; Smith TJ
    Lancet Diabetes Endocrinol; 2021 Jun; 9(6):360-372. PubMed ID: 33865501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intraocular pressure improvement in patients receiving teprotumumab for the treatment of thyroid eye disease: a case series.
    Chu M; Sung J; Song M; Song A; Song J
    J Med Case Rep; 2022 May; 16(1):195. PubMed ID: 35538553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Teprotumumab for the Treatment of Active Thyroid Eye Disease.
    Douglas RS; Kahaly GJ; Patel A; Sile S; Thompson EHZ; Perdok R; Fleming JC; Fowler BT; Marcocci C; Marinò M; Antonelli A; Dailey R; Harris GJ; Eckstein A; Schiffman J; Tang R; Nelson C; Salvi M; Wester S; Sherman JW; Vescio T; Holt RJ; Smith TJ
    N Engl J Med; 2020 Jan; 382(4):341-352. PubMed ID: 31971679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful Case of Teprotumumab Treatment in an Adolescent Patient With Thyroid Eye Disease.
    Radulovich N; Van Brummen A; Chambers C; Zhang M
    Ophthalmic Plast Reconstr Surg; 2024 Mar-Apr 01; 40(2):e65-e67. PubMed ID: 38231594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Teprotumumab for the treatment of thyroid eye disease.
    Ju Y; Yang J
    Expert Rev Clin Immunol; 2020 Aug; 16(8):739-743. PubMed ID: 32707005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acquired lower eyelid epiblepharon in thyroid-associated ophthalmopathy of Koreans.
    Park SW; Khwarg SI; Kim N; Lee MJ; Choung HK
    Ophthalmology; 2012 Feb; 119(2):390-5. PubMed ID: 21978591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bilateral dysthyroid compressive optic neuropathy responsive to teprotumumab.
    Hwang CJ; Nichols EE; Chon BH; Perry JD
    Eur J Ophthalmol; 2022 May; 32(3):NP46-NP49. PubMed ID: 33525898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Teprotumumab (Tepezza): from the discovery and development of medicines to USFDA approval for active thyroid eye disease (TED) treatment.
    Ali F; Chorsiya A; Anjum V; Ali A
    Int Ophthalmol; 2021 Apr; 41(4):1549-1561. PubMed ID: 33481154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Teprotumumab: First Approval.
    Markham A
    Drugs; 2020 Apr; 80(5):509-512. PubMed ID: 32157641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Teprotumumab: Interpreting the Clinical Trials in the Context of Thyroid Eye Disease Pathogenesis and Current Therapies.
    Winn BJ; Kersten RC
    Ophthalmology; 2021 Nov; 128(11):1627-1651. PubMed ID: 33930408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Objective Diplopia Outcomes for Patients Treated With Teprotumumab for Thyroid Eye Disease.
    Mudalegundi S; Huang P; Henderson AD; Carey AR
    J Neuroophthalmol; 2024 Mar; 44(1):80-86. PubMed ID: 38294416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thyroid Eye Disease, Teprotumumab, and Hearing Loss: An Evolving Role for Otolaryngologists.
    Chern A; Dagi Glass LR; Gudis DA
    Otolaryngol Head Neck Surg; 2021 Dec; 165(6):757-758. PubMed ID: 33781112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Teprotumumab: a novel therapeutic monoclonal antibody for thyroid-associated ophthalmopathy.
    Slentz DH; Nelson CC; Smith TJ
    Expert Opin Investig Drugs; 2020 Jul; 29(7):645-649. PubMed ID: 32429706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapidly progressive cognitive decline associated with teprotumumab in thyroid eye disease.
    Hoang TD; Nguyen NT; Chou E; Shakir MK
    BMJ Case Rep; 2021 May; 14(5):. PubMed ID: 33972303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of teprotumumab infusion on ocular alignment in patients with symptomatic thyroid eye disease.
    Zhang C; Ersan S; Yousef Y; Sandhur B; Desilets J; McGlone C; Kellner T; Teru S; Reynolds AL
    J AAPOS; 2024 Aug; 28(4):103959. PubMed ID: 38944235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Teprotumumab: A Review in Thyroid Eye Disease.
    Nie T; Lamb YN
    Drugs; 2022 Nov; 82(17):1663-1670. PubMed ID: 36418673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Teprotumumab for Asymmetric Thyroid Eye Disease.
    Ugradar S; Wang Y; Douglas R
    Ophthalmology; 2021 Oct; 128(10):1416. PubMed ID: 34556309
    [No Abstract]   [Full Text] [Related]  

  • 19. A Review of Novel Medical Treatments for Thyroid Eye Disease.
    Park JW; Yoon JS
    Korean J Ophthalmol; 2024 Jun; 38(3):249-259. PubMed ID: 38773958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thyroid Eye Disease-Related Epiblepharon: A Comparative Case Study.
    Zhao J; Hodgson NM; Chang JR; Campbell AA; McCulley TJ
    Asia Pac J Ophthalmol (Phila); 2020; 9(1):44-47. PubMed ID: 31990745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.